1. Pink Sheet

UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

 
• By Cathy Kelly

US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.

House of mirrors
What does UnitedHealthcare's decision on Neulasta and its biosimilars reflect? That depends on where you stand.

[UnitedHealthCare]’s decision to give Amgen Inc.’s Neulasta preferred formulary status over pegfilgrastim biosimilars in return for a significant rebate is getting attention as US policymakers consider ways to promote uptake of biosimilars and reduce drug costs.

Beginning July 1 in UnitedHealthCare's commercial and community plans, use of Neulasta Onpro or Neulasta in a vial will be required before coverage is granted for the two pegfilgrastim biosimilars on the market – Mylan NV and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.